SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome Therapeutics presented new data on AXS-12 and solriamfetol at…

Axsome Therapeutics, Inc. · PRESS-RELEASE filed Jun 15, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Jun 15, 2026 at 07:00 ET

Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes from the Phase 3 ENCORE trial and post-hoc composite endpoint analyses. The presentations do not contain new regulatory milestones, financial results, or concrete catalysts, this is a routine scientific conference update without material new information for the stock.

  • Presented Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
  • Presented post-hoc composite endpoint analysis of solriamfetol Phase 3 trials in narcolepsy and OSA
  • Presented subgroup analysis from CRESCENDO survey on residual cataplexy symptom burden
  • No new approvals, regulatory submissions, or financial guidance were announced

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access